US Pharma MarketingRallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo
Rallybio swerves past Candid pothole to land deal with cancer drug developer Avenzo is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Rallybio has steered its way to a new reverse merger, inking a deal with Avenzo Therapeutics weeks after a UCB buyout took its former partner off the market.
Source: FierceBiotech